The Food and Drug Administration
covid-19
Regeneron Pharmaceuticals
Eli Lilly
FDA
The Centers for Disease Control and Prevention
GlaxoSmithKline
Vir Biotechnology —
Pfizer
Merck
Ridgeback Biotherapeutics
DeSantis
the National Institutes of Health
CDC
PCR
the White House
N95
Post
Biden
Ron DeSantis
Christina Pushaw
Fauci
Mask
N95s
covid-19
Americans
No matching tags
No matching tags
Pfizer
Florida
medications.“Frankly
U.S.
No matching tags
The Food and Drug Administration is poised as soon as Monday to restrict two monoclonal antibodies, saying the covid-19 treatments should not be employed in any states because they are ineffective against the dominant omicron variant, according to two senior administration health officials.As a result, the Biden administration will pause distribution of the therapies, manufactured by Regeneron Pharmaceuticals and Eli Lilly, to the states.“We want to make sure that patients get treatments that are effective, not treatments that don’t work,” said one of the officials, who spoke on the condition of anonymity to describe internal discussions.The FDA action will involve revising the emergency use authorizations for the monoclonal antibodies.
As said here by Laurie McGinley